"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

Review article
peer-reviewed

When to Use Antibiotics in COVID-19: A Proposal Based on Questions



Abstract

The COVID-19 pandemic has affected millions of people, including hundreds of deaths. The search for adequate treatments and interventions that influence poor prognostic factors and reduce mortality has led to excessive use of antibiotics based on the possible existence of bacterial co-infection. However, there is no evidence to justify the systematic use of antimicrobials in COVID-19. The recommendations seek to provide knowledge regarding treatment; standardizing a management algorithm requires validation in clinical trials and studies of greater methodological rigor.

Introduction & Background

Even though COVID-19 is a viral disease, the frequent use of antibacterial agents for its treatment is a concern [1]. During the initial stages of the pandemic, there was an indiscriminate use of these agents based on the fact that viral respiratory infections predispose to bacterial superinfection [1]. A meta-analysis established the presence of bacterial co-infection in COVID-19 at 7%, increasing to 14% in the population of the ICU [2]. These results are far from those presented in other viral infections such as influenza A H1N1, where bacterial co-infection was estimated in 30% of cases, behaving as an independent mortality factor [3]. Furthermore, these infections could negatively impact innate and adaptive immunity since they surpass the weakened immunological barrier, causing fatal clinical complications [1].

It is worth mentioning that respiratory failure from COVID-19 pneumonia is the commonest cause of death [4]

The clinical spectrum of COVID-19 varies from paucisymptomatic forms to critical illnesses that may initially mimic a common cold. On the other hand, imaging modalities often show abnormalities in the more advanced stages of infection [1,5,6]. Therefore, differentiating COVID-19 from other infectious states (bacterial or viral) is difficult [1,5,6]. In short, in our midst, limited resources make it even more challenging to distinguish between COVID-19 and bacterial superinfection, or co-infection. All these factors present a challenge when applying a policy of rational use of antibiotics [1,5,6].

This review aims to describe the available evidence on antimicrobial management of COVID-19 and propose a strategy for their appropriate use.

Review

How does the infection occurs?

Several phases in the development of COVID-19 have been described [7,8]. SARS-CoV-2, the etiological agent, binds to cells through the ACE-2 receptor and, after endocytosis, fuses with endosomes, initiating stage I or the viral phase. Subsequently, the virus releases its RNA intracellularly, and the host cell organelles are used to replicate the peptide chains and produce new viruses [8]. Finally, SARS-CoV-2 virions are released from the host cell by exocytosis and invade nearby cells (Figure 1) [9].

After respiratory and alveolar dissemination, stage II (symptomatic) begins. This stage is also called the acute or critical phase. As it progresses through the bloodstream, the virus reaches other organs and systems [10]. By invading epithelial cells, SARS-CoV-2 stimulates an immune-mediated inflammatory response, giving rise to stage III ( hyperinflammatory), where tissue damage, endothelial dysfunction, and exaggerated release of cytokines occur, namely IFN-γ, TNF-α, IL -1, IL-10, IL-7, IL-2, IL-6 [11]. This leads to the activation of procoagulant factors, increased permeability, inflammation, vascular dilation, along with intravascular coagulation, ischemia, thrombosis, pulmonary edema, respiratory failure, and multiple organ failure [12-15].

During phase II or III, the immune response, amount of cytokines, and inflammatory mediators can be modulated, achieving effective control of the virus, clinical improvement, and increased number and functionality of T lymphocytes; this is called the recovery phase (Figure 2) [7,8].

What do we use to treat COVID-19?

Early in the pandemic, there were no specific therapeutic interventions. Initially, antiviral drugs such as lopinavir/ritonavir, remdesivir; interferons; convalescent plasma; antimalarials (chloroquine or hydroxychloroquine); and ivermectin were used. Nevertheless, today there is solid evidence against its use, even showing deleterious effects [16]. Therefore, in addition to symptomatic treatment, different options have been proposed for the most critical phases of the disease [17,18].

Recently, targeted antiviral therapy (molnupiravir, paxlovid) and anti-SARS-CoV-2 monoclonal antibodies (bamlanivimab/etesevimab, casirivimab/imdevimab) have been approved under FDA issued Emergency Use Authorization (EUA) [19]. However, they do not decrease mortality.

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) study showed that when using dexamethasone, there was a notable decrease in 28-day mortality in critically ill patients with COVID-19 and a lower oxygen requirement, especially invasive mechanical ventilation (IMV) [20]. Furthermore, a retrospective cohort found that the likelihood of developing secondary infection was not significantly affected by corticosteroid administration (HR: 1.45, CI: 0.75-2.82, p=0.28), and this was held constant in the sub-analysis examining blood, urine, and sputum cultures to prove any sign of bacterial infection; concluding that the diagnosis of bacterial superinfection did not have a significant impact on the probability of mortality in 28 days (HR: 0.66, CI: 0.33-1.35, p=0.25) [21].

Another endorsed drug is tocilizumab, an IL-6 inhibitor, which reduces mortality and IMV requirements without significantly increasing serious adverse events [22]. However, a single-center cohort found that the use of tocilizumab was associated with a higher proportion of bacterial superinfection (54% vs. 26%; p<0.001); no difference in the 28-day case fatality rate among tocilizumab-treated patients who developed bacterial superinfection (22% vs. 15%; p=0.42) [22].

Antibiotics/Antimicrobial resistance: a latent threat

Antibiotics do not directly affect SARS-CoV-2, but viral respiratory infections predispose to bacterial pneumonia [1]. Although, the use of antibiotics with antiviral properties has been proposed [18], macrolides such as azithromycin have antiviral actions in addition to anti-inflammatory actions by attenuating the immune response, effects ruled out by current evidence [23, 24].

It is worth mentioning that co-infection is the existence of a bacterial infection within the first 48 hours of the diagnosis of COVID-19, confirmed by culture of orotracheal secretion or blood cultures, molecular panels for viruses and bacteria and/or antigenic detection methods [2]. Superinfection or secondary infection is the appearance of a bacterial infection after 48 hours of admission, with at least one positive culture of a respiratory sample (endotracheal aspirate, bronchoalveolar lavage), blood culture, urine culture, or the result of molecular tests, such as multiplex PCR and, in a clinical context, consistent with infection [2]. Secondary infections are used to be considered healthcare-associated infections.

The specific occurrence of bacterial superinfection in COVID-19 is unclear. Although it is estimated that 3-10% of patients may present it, a meta-analysis placed these figures at around 7% [2,25,26]. A randomized cohort found that 57% of patients with COVID-19 received antibiotics in the first 48 hours of hospital admission, and less than 4% were diagnosed with bacterial co-infection [27]. Another review determined that more than 72% of patients with COVID-19 received antimicrobial therapy, only 8% meriting it [28]. The high prescription of antibiotics occurred mainly during the first peak of the health emergency, with higher rates of ICU admission [29]. In addition, broader-spectrum antibiotics were used during the weeks with the highest number of cases [30].

The use of antibiotics promotes the growth and proliferation of bacterial microorganisms capable of resisting their antimicrobial properties, known as bacterial resistance [31]. Since the beginning of the pandemic, several investigations have reported an increase in multidrug resistance in bacterial and fungal infections [3,29].

It has been seen that the resistance of Staphylococcus aureus against clindamycin, erythromycin, and oxacillin is up to 90% [29]. One study found 53% resistance to erythromycin in Streptococcus pyogenes, 58% to tetracyclines, and co-resistance to both drugs in 40% [32]. The frequency of methicillin-resistant S. aureus has increased, and studies in patients with bacterial infections secondary to COVID-19 show methicillin resistance in all strains of coagulase-negative Staphylococcus and S. aureus [33].

Gram-negative bacteria have acquired higher rates of antimicrobial resistance, including Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae [34]. Resistance has been described in 76% and 91% to carbapenems in K. pneumoniae and A. baumannii, respectively [33]. A study in patients with COVID-19 showed Enterobacteriaceae resistance to cefepime at 43%, ceftazidime at 47%, piperacillin at >67%, and trimethoprim-sulfamethoxazole at 75%. All of them showed amikacin susceptibility [29]. There are already reports of acquired resistance to ceftolozane-tazobactam and ceftazidime-avibactam.

This phenomenon is a major public health problem that claims thousands of lives annually worldwide [35], and it is estimated that by 2050 it could reach 10 million deaths [36].

Learned lessons

Safe antimicrobial stewardship strategies aim to limit indiscriminate use to decrease antimicrobial resistance [29]. The use of antibiotics in COVID-19 is not yet standardized, and there is no evidence for their routine use. Instead, factors have been proposed that determine infectious-bacterial processes that warrant its use (Table 1).

Predictors of bacterial co-infection in COVID-19
Clinical features
New onset or exacerbation of fever
Changes in sputum characteristics
Progressive clinical deterioration
Laboratory test
Signs of organ failure
Leukocytosis
Neutrophilia and lymphocytopenia
Increased C-reactive protein
Increased levels of procalcitonin
Images
New lobular consolidation patterns in chest X-ray

Condition of the Patient

The clinical and hemodynamic condition of the patient is essential to suspect bacterial coinfection. For example, in patients with COVID-19, the presence of signs of systemic inflammatory response, dyspnea, persistent fever, tachycardia, and data of unexplained tissue hypoperfusion before day 7 of symptoms are useful to identify additional infectious processes [37].

Studies have shown increased sputum production in patients with bacterial coinfection [27]. In addition, a change in the characteristics of the sputum and the return or exacerbation of febrile episodes may also indicate the development of underlying bacterial pathology [38].

Lab Tests

The role of inflammatory biomarkers in favoring decision-making has been evaluated. One study found that electrolyte disturbances, anemia, hypoproteinemia, and signs of organ failure such as acute liver function impairment, acute kidney injury, troponin-mediated heart damage, and death were higher in the group of patients with high suspicion of bacterial pneumonia added to COVID-19 [37]. D-dimer levels increased in patients with COVID-19, being normal in bacterial pneumonia [38].

C-reactive protein (CRP) is used to guide the use of tocilizumab; however, bacterial superinfection must be ruled out. Nevertheless, studies defend the usefulness of CRP for initiating antibiotics since they found that patients with COVID-19 and coinfection had higher levels than controls [39,40]. Therefore, it is proposed to combine clinical and laboratory parameters to define the presence of bacterial coinfection.

Leukocytosis is not an absolute criterion for the existence of bacterial coinfections, taking into account phenomena such as the demarginalization of leukocytes after the use of steroids. However, the authors state that in patients with confirmed coinfection, in the absence of steroid use, there is a higher leukocyte count [25,41]. Others refer that lymphocytosis is characteristic of viral pathologies and that a 25% increase in leukocytes is suggestive of the development of bacterial processes with a positive predictive value of 85.71% [38,41].

Usefulness of Procalcitonin

Despite the controversy over the usefulness of procalcitonin (PCT) in differentiating viral-bacterial etiologies [42], several publications show that elevated PCT is associated with the severity of SARS-CoV-2 infection.

One study found that more than 70% of COVID-19 patients without co-infection at admission had PCT values <0.25 ng/mL [43]. PCT has a high negative predictive value in the diagnosis of bacterial co-infection if it is <0.1 ng/ml [27]. When it is ≥0.1 ng/ml, it could be related to bacterial co-infection and greater severity in patients with COVID-19 [44]. A ferritin/procalcitonin (F/P) ratio >1250 is useful for differentiating bacterial pneumonia and COVID-19 (sensitivity: 78%, specificity: 59%, and area under the receiver operating characteristic [ROC] curve: 0.79 [OR: 4.9; CI: 1.5-16.1, p=0.009]) [45]. Likewise, higher ferritin concentrations have been seen in the group of patients with COVID-19 without bacterial co-infection and higher PCT levels in bacterial pneumonia [45]. Further studies are required to assess the accuracy and efficacy of this index.

Radiological Findings

The American College of Radiology recommends radiography as the initial image for patients with respiratory symptoms. CT is more sensitive, it allows to characterize the lesions, classifying the findings into opacities due to bacterial infection versus the typical ground glass opacities seen in COVID-19 [38,46].

There are atypical radiological findings that make us consider a different etiology, such as budding or subpleural tree nodules, cavitations, isolated or multilobe consolidation without ground glass, loculated pleural effusion, and mediastinal lymph adenomegaly [47,48]. The presence of new bilateral opacities or consolidation pattern were found in almost all patients with bacterial superinfection, and infrequent in COVID-19 without superinfection [38].

Proposed management

It is suggested to classify the patient according to the severity of the disease based on clinical and laboratory test criteria. Patients with mild-to-moderate disease benefit from symptomatic management without antibiotics. Regardless of clinical classification, patients should be closely monitored. In critically ill patients, a useful tool is the calculation of sequential organ failure assessment (SOFA) and delta-SOFA, which determines the degree of organic dysfunction upon admission to the ICU and during its stay [49,50].

In patients with severe disease, it is necessary to perform a chest CT to assess the presence of typical radiological signs of COVID-19 or bacterial processes that indicate taking cultures and early initiation of antibiotic therapy. Laboratory test results showed elevated PCT, leukocytosis with neutrophilia, and evidence of objective multi-organ damage suggest bacterial infection, requiring serial cultures and antibiotic treatment according to epidemiology, antimicrobial susceptibility patterns, established management guidelines, and local guidelines of bacterial resistance; always choosing the antimicrobial with less collateral damage.

If the suspicion of added infection persists without an established infectious focus, cultures should be taken to rule out hidden sources of infection. Initiation of antibiotics is not recommended until positive cultures are obtained.

If the diagnosis of bacterial co-infection or superinfection was determined after 72 hours of clinical and microbiological surveillance, patients who show improvement and have positive cultures should continue the established antimicrobial regimen, discontinue antibiotics with a narrower spectrum, or redirect to another antimicrobial depending on the microbiological isolation obtained. In case of negative cultures and low pre-test probability, it is recommended to suspend antibiotics. If the pre-test probability is high, a new PCT measurement is recommended to define antibiotic suspension.

When there is no improvement or there is clinical deterioration, obtaining negative cultures requires searching for another agent, microorganisms, or foci not covered with the current scheme. In addition, new cultures must be performed. In patients without clinical improvement with positive cultures, co-infections and other sites of infection should be sought while assessing the need to increase the dose of antibiotics used at the time or to stagger antimicrobial therapy if poor penetration is noted in the tissues of the drug used or an inappropriate spectrum in relation to the microorganism found in the culture.

Finally, in patients with progressive clinical worsening or biphasic clinical behavior, a new radiological evaluation should be performed in search of imaging signs typical of COVID-19 or suggestive of bacterial pathology, in addition to taking cultures. The duration of antimicrobial treatment should be as short as possible (Figure 3).

Conclusions

The health emergency has led to the indiscriminate use of antibiotics, leading to severe consequences such as an increase in allergies, costs to the health system, and the increase in resistant strains. To date, most of the research on COVID-19 has very low methodological quality, which makes it challenging to use and apply. There is no consensus to discriminate between SARS-CoV-2 infection and bacterial coinfection or superinfection due to their similarity in presentation. Clinical condition and laboratory tests are important predictors that can help discern when to start antibiotics considering the local antibiogram. Frequent evaluations should be made to determine the continuity or staggering use of the antibiotics.


References

  1. Beović B, Doušak M, Ferreira-Coimbra J, et al.: Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020, 75:3386-3390. 10.1093/jac/dkaa326
  2. Lansbury L, Lim B, Baskaran V, Lim WS: Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020, 81:266-275. 10.1016/j.jinf.2020.05.046
  3. Tiri B, Sensi E, Marsiliani V, et al.: Antimicrobial stewardship program, COVID-19, and infection control: spread of carbapenem-resistant Klebsiella pneumoniae colonization in ICU COVID-19 patients. What did not work?. J Clin Med. 2020, 9:10.3390/jcm9092744
  4. Fayed M, Patel N, Yeldo N, et al.: Effect of intubation timing on the outcome of patients with severe respiratory distress secondary to COVID-19 pneumonia. Cureus. 2021, 13:e19620. 10.7759/cureus.19620
  5. Pulia MS, Wolf I, Schulz LT, Pop-Vicas A, Schwei RJ, Lindenauer PK: COVID-19: an emerging threat to antibiotic stewardship in the emergency department. West J Emerg Med. 2020, 21:1283-1286. 10.5811/westjem.2020.7.48848
  6. Ding Q, Lu P, Fan Y, Xia Y, Liu M: The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020, 92:1549-1555. 10.1002/jmv.25781
  7. Siddiqi HK, Mehra MR: COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020, 39:405-407. 10.1016/j.healun.2020.03.012
  8. Lin L, Lu L, Cao W, Li T: Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020, 9:727-732. 10.1080/22221751.2020.1746199
  9. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V: Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021, 19:155-170. 10.1038/s41579-020-00468-6
  10. Zaim S, Chong JH, Sankaranarayanan V, Harky A: COVID-19 and multiorgan response. Curr Probl Cardiol. 2020, 45:100618. 10.1016/j.cpcardiol.2020.100618
  11. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L: SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020, 54:62-75. 10.1016/j.cytogfr.2020.06.001
  12. Leisman DE, Deutschman CS, Legrand M: Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020, 46:1105-1108. 10.1007/s00134-020-06059-6
  13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ: COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395:1033-1034. 10.1016/S0140-6736(20)30628-0
  14. Ackermann M, Verleden SE, Kuehnel M, et al.: Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020, 383:120-128. 10.1056/NEJMoa2015432
  15. Varga Z, Flammer AJ, Steiger P, et al.: Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020, 395:1417-1418. 10.1016/S0140-6736(20)30937-5
  16. Update to living WHO guideline on drugs for covid-19. BMJ. 2022, 378:m3379. 10.1136/bmj.o1713
  17. Diao B, Wang C, Tan Y, et al.: Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020, 11:827. 10.3389/fimmu.2020.00827
  18. Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P: COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Intern Emerg Med. 2021, 16:281-308. 10.1007/s11739-020-02569-9
  19. Coopersmith CM, Antonelli M, Bauer SR, et al.: The surviving sepsis campaign: research priorities for coronavirus disease 2019 in critical illness. Crit Care Med. 2021, 49:598-622. 10.1097/CCM.0000000000004895
  20. Horby P, Lim WS, Emberson JR, et al.: Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:693-704. 10.1056/NEJMoa2021436
  21. Ritter LA, Britton N, Heil EL, et al.: The impact of corticosteroids on secondary infection and mortality in critically ill COVID-19 patients. J Intensive Care Med. 2021, 36:1201-1208. 10.1177/08850666211032175
  22. Somers EC, Eschenauer GA, Troost JP, et al.: Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2021, 73:e445-e454. 10.1093/cid/ciaa954
  23. Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B: Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther. 2020, 108:201-211. 10.1002/cpt.1857
  24. Cavalcanti AB, Zampieri FG, Rosa RG, et al.: Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020, 383:e119. 10.1056/NEJMx200021
  25. Nasir N, Rehman F, Omair SF: Risk factors for bacterial infections in patients with moderate to severe COVID-19: a case-control study. J Med Virol. 2021, 93:4564-4569. 10.1002/jmv.27000
  26. Langford BJ, So M, Raybardhan S, et al.: Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020, 26:1622-1629. 10.1016/j.cmi.2020.07.016
  27. Vaughn VM, Gandhi TN, Petty LA, et al.: Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis. 2021, 72:e533-e541. 10.1093/cid/ciaa1239
  28. Rawson TM, Moore LS, Zhu N, et al.: Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020, 71:2459-2468. 10.1093/cid/ciaa530
  29. Chowdhary A, Tarai B, Singh A, Sharma A: Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April-July 2020. Emerg Infect Dis. 2020, 26:2694-2696. 10.3201/eid2611.203504
  30. Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, et al.: Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic. Antibiotics (Basel). 2021, 10:10.3390/antibiotics10020132
  31. Contreras-Omaña R, Escorcia-Saucedo AE, Velarde-Ruiz Velasco JA: Prevalence and impact of antimicrobial resistance in gastrointestinal infections: a review. Rev Gastroenterol Mex (Engl Ed). 2021, 86:265-275. 10.1016/j.rgmxen.2021.06.004
  32. Mahmoudi H: Bacterial co-infections and antibiotic resistance in patients with COVID-19. GMS Hyg Infect Control. 2020, 15:35. 10.3205/dgkh000370
  33. Abraham T, Sistla S: Trends in antimicrobial resistance patterns of Group A streptococci, molecular basis and implications. Indian J Med Microbiol. 2018, 36:186-191. 10.4103/ijmm.IJMM_18_107
  34. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, Zhang Y: Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control. 2020, 9:153. 10.1186/s13756-020-00819-1
  35. Subramaniam G, Girish M: Antibiotic resistance - a cause for reemergence of infections. Indian J Pediatr. 2020, 87:937-944. 10.1007/s12098-019-03180-3
  36. Gasser M, Zingg W, Cassini A, Kronenberg A: Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in Switzerland. Lancet Infect Dis. 2019, 19:17-18. 10.1016/S1473-3099(18)30708-4
  37. Liu C, Wen Y, Wan W, Lei J, Jiang X: Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Int Immunopharmacol. 2021, 90:107157. 10.1016/j.intimp.2020.107157
  38. Wu CP, Adhi F, Highland K: Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19. Cleve Clin J Med. 2020, 87:659-663. 10.3949/ccjm.87a.ccc015
  39. Maruyama T, Fujisawa T, Ishida T, et al.: A therapeutic strategy for all pneumonia patients: a 3-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2019, 68:1080-1088. 10.1093/cid/ciy631
  40. Mason CY, Kanitkar T, Richardson CJ, et al.: Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J Antimicrob Chemother. 2021, 76:1323-1331. 10.1093/jac/dkaa563
  41. Falcone M, Tiseo G, Giordano C, et al.: Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021, 76:1078-1084. 10.1093/jac/dkaa530
  42. Nori P, Cowman K, Chen V, et al.: Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2021, 42:84-88. 10.1017/ice.2020.368
  43. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM: Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020, 70:538-542. 10.1093/cid/ciz545
  44. Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-1062. 10.1016/S0140-6736(20)30566-3
  45. Xu JB, Xu C, Zhang RB, et al.: Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020, 10:15058. 10.1038/s41598-020-72164-7
  46. Gharamti AA, Mei F, Jankousky KC, et al.: Diagnostic utility of a ferritin-to-procalcitonin ratio to differentiate patients with COVID-19 from those with bacterial pneumonia: a multicenter study. Open Forum Infect Dis. 2021, 8:ofab124. 10.1093/ofid/ofab124
  47. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J: COVID-19: don't neglect antimicrobial stewardship principles!. Clin Microbiol Infect. 2020, 26:808-810. 10.1016/j.cmi.2020.04.024
  48. Prokop M, van Everdingen W, van Rees Vellinga T, et al.: CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology. 2020, 296:E97-E104. 10.1148/radiol.2020201473
  49. García-Gigorro R, Sáez-de la Fuente I, Marín Mateos H, Andrés-Esteban EM, Sanchez-Izquierdo JA, Montejo-González JC: Utility of SOFA and Δ-SOFA scores for predicting outcome in critically ill patients from the emergency department. Eur J Emerg Med. 2018, 25:387-393. 10.1097/MEJ.0000000000000472
  50. Fayed M, Patel N, Angappan S, Nowak K, Vasconcelos Torres F, Penning DH, Chhina AK: Sequential organ failure assessment (SOFA) score and mortality prediction in patients with severe respiratory distress secondary to COVID-19. Cureus. 2022, 14:e26911. 10.7759/cureus.26911

Review article
peer-reviewed

When to Use Antibiotics in COVID-19: A Proposal Based on Questions


Author Information

Carmelo Dueñas-Castell

Intensive Care Medicine, Gestión Salud IPS, Cartagena, COL

Camilo Jose Polanco-Guerra

Internal Medicine, Universidad del Sinú - Elías Bechara Zainúm, Cartagena, COL

Maria Cristina Martinez-Ávila Corresponding Author

Intensive Care Medicine, Nuevo Hospital de Bocagrande, Cartagena, COL

Amilkar J. Almanza Hurtado

Intensive Care Medicine, Universidad de Cartagena, Cartagena, COL

Tómas Rodriguez Yanez

Critical Care Medicine, Universidad de Cartagena, Cartagena, COL

Juan Camilo Gutierrez-Ariza

Critical Care Medicine, Clinica La Ermita, Cartagena, COL

Jorge Rico-Fontalvo

Nephrology, La Asociación Colombiana de Nefrología e Hipertensión Arterial, Bogotá, COL


Ethics Statement and Conflict of Interest Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.



Review article
peer-reviewed

When to Use Antibiotics in COVID-19: A Proposal Based on Questions


Figures etc.

SIQ
-
RATED BY 0 READERS
CONTRIBUTE RATING

Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.